MedSciNet is implementing the online database for the “Boost Brittle Bones Before Birth” (BOOSTB4) project, which is coordinated by Karolinska Institutet but will be run as a collaboration between several leading European research centres and companies. For the first time, a study will be conducted involving the transplantation of stem cells into fetuses with the brittle-bone disease osteogenesis imperfecta, which causes repeated fractures, often before birth.
Children born with the severe form of osteogenesis imperfecta, or congenital brittle bone disease, are often seriously ill. Repeated fractures in all parts of the skeleton give rise to physical disabilities, postural aberration, and stunted growth. The child’s breathing and pulmonary function can also be affected with the contraction of the rib cage. There is currently no cure for this condition.
Collagen is a thread-like protein found in bone that has a similar reinforcing function to iron rods in concrete. Since the disease is caused by an inability of the developing body to form collagen, scientists at Karolinska Institutet have produced a special strain of stem cell, which when injected into the body of sufferers targets and strengthens the bone by producing collagen. Studies on mice have shown a positive response to the treatment, which has also been tried on a couple of children with the disease.
“The oldest child to have received the treatment is now 13 and is performing better than expected and is still growing,” says Cecilia Götherström", researcher at Karolinska Institutet’s Department of Clinical Sciences, Intervention and Technology. “But we believe that we can improve the treatment for other patients by administering it to the fetus and again in repeated doses during the child’s first years of life.”
Dr Götherström will be leading the study that is to test the treatment on unborn babies. Thirty babies will be included in the study, half of which will receive a stem-cell graft before birth, and half after. New transplantations will then be done at six-month intervals over a period of two years to enhance the effect. The researchers will then assess the results by counting the number of fractures the children in both groups suffer and comparing the results with children who have not been treated with stem cells.
The “Boost Brittle Bones Before Birth” (BOOSTB4) project will start in January 2016 and will be coordinated by Karolinska Institutet. Other participating research centres and companies include University College London, Great Ormond Street Hospital, the University of Leicester, Universitair Medisch Centrum Utrecht, Leiden University Medical Centre, Uniklinik Köln, Lund University, Cell Protect Nordic Pharmaceuticals, Nordic Health Economics, MedSciNet and Euram Ltd. The study will also include patients from other European countries. Funding has been obtained from several sources, including the Swedish Research Council and Horizon 2020, the EU framework programme for research and innovation.
Read more about the BOOSTB4 study here.